Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 5:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Guanfacine Clear all
Terminated Not applicable Interventional Accepts healthy volunteers Results available

An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD

NCT02259517
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine, Lisdexamfetamine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
6 Years to 17 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Jul 24, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study

NCT04742673
View directory record Official record
Conditions
Critical Illness, Delirium, Cognitive Impairment
Interventions
Guanfacine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jul 24, 2026, 5:03 AM EDT
Completed Phase 4 Interventional Results available

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

NCT01238575
View directory record Official record
Conditions
Pervasive Development Disorders
Interventions
placebo, extended-release guanfacine
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
5 Years to 14 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Jul 24, 2026, 5:03 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)

NCT06042257
View directory record Official record
Conditions
Hyperactivity in Children With Down Syndrome, Impulsivity in Children With Down Syndrome
Interventions
Guanfacine Hydrochloride Immediate Release, Placebo
Drug
Lead sponsor
Rachel G. Greenberg, MD, MB, MHS
Other
Eligibility
6 Years to 12 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
14
States / cities
Phoenix, Arizona • Atlanta, Georgia • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 24, 2026, 5:03 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Mechanistic Evaluation of Guanfacine on Drinking Behavior in Women and Men With Alcohol Use Disorders

NCT03764098
View directory record Official record
Conditions
Alcohol Use
Interventions
Guanfacine ER, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
21 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 24, 2026, 5:03 AM EDT
Terminated Phase 4 Interventional

Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance

NCT01681264
View directory record Official record
Conditions
Chronic Pain
Interventions
Morphine, Guanfacine 1mg, Guanfacine 2mg, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 24, 2026, 5:03 AM EDT
Completed Phase 4 Interventional

Inuniv and Working Memory

NCT01177306
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
extended release guanfacine
Drug
Lead sponsor
Lori A. Schweickert, MD
Individual
Eligibility
8 Years to 12 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2014 · Synced Jul 24, 2026, 5:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects

NCT01600885
View directory record Official record
Conditions
NMDA Receptor Function
Interventions
Guanfacine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
3
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Jul 24, 2026, 5:03 AM EDT
Withdrawn Phase 4 Interventional

Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome

NCT04066088
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Placebo, Guanfacine extended release (GXR)
Other · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
6 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Jul 24, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms

NCT00367835
View directory record Official record
Conditions
ADHD
Interventions
SPD503 (Guanfacine hydrochloride), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
34
States / cities
Phoenix, Arizona • El Centro, California • Rolling Hills Estates, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Jul 24, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

The Effect of Guanfacine on Delirium in Critically Ill Patients

NCT04578886
View directory record Official record
Conditions
Delirium
Interventions
Guanfacine, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Jul 24, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

PK/PD Comparison of Guanfacine ER and IR

NCT01904526
View directory record Official record
Conditions
Smoking
Interventions
Guanfacine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Jul 24, 2026, 5:03 AM EDT
Not yet recruiting Phase 4 Interventional

Treating Young Children With Attention Deficit Hyperactivity Disorder

NCT07300956
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Guanfacine (GUA), Methylphenidate (MPH)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 5 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Palo Alto, California • Boston, Massachusetts • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 24, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Guanfacine Clinical Trial for Smoking Cessation

NCT02051309
View directory record Official record
Conditions
Smoking Cessation
Interventions
Guanfacine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Jul 24, 2026, 5:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Norepinephrine in Emotional Processing

NCT00109642
View directory record Official record
Conditions
Psychopathy, Mental Disorders
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
20 Years to 50 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 24, 2026, 5:03 AM EDT
Withdrawn Phase 4 Interventional

Guanfacine Extended Release and Mindfulness Skills Therapy

NCT03258476
View directory record Official record
Conditions
Stress Disorder
Interventions
Guanfacine Extended Release, Mindfulness Skills Therapy, Placebo
Drug · Behavioral
Lead sponsor
UConn Health
Other
Eligibility
10 Years to 20 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 7, 2021 · Synced Jul 24, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

Modeling Stress-precipitated Smoking Behavior for Medication Development

NCT00773357
View directory record Official record
Conditions
Smoking
Interventions
guanfacine, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Jul 24, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

Guanfacine to Improve Substance Use Outcomes in Women

NCT03980184
View directory record Official record
Conditions
Substance Use Disorders
Interventions
Guanfacine, Behavioral Counseling
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Jul 24, 2026, 5:03 AM EDT
Completed Phase 4 Interventional Results available

Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder

NCT00429273
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Guanfacine, Methylphenidate (MPH)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
7 Years to 14 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Jul 24, 2026, 5:03 AM EDT
Recruiting Phase 1 Interventional

Combined Guanfacine and Mindfulness Meditation as an Adjunct to Buprenorphine Maintenance in Opioid Use Disorder

NCT06642181
View directory record Official record
Conditions
Mindfulness, Guanfacine, Opioid Use Disorder
Interventions
Guanfacine pharmacotherapy, Mindfulness Oriented Recovery Enhancement (MORE)
Drug · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 55 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Jul 24, 2026, 5:03 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Pharmacology of Cognition in Schizotypal Personality Disorder

NCT00353379
View directory record Official record
Conditions
Schizotypal Personality Disorder, Personality Disorders
Interventions
Guanfacine, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Jul 24, 2026, 5:03 AM EDT
Completed Phase 4 Interventional Results available

The BIomarker Guided (BIG) Study for Depression

NCT04181736
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Guanfacine Tablets
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 69 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Jul 24, 2026, 5:03 AM EDT
Completed Phase 4 Interventional Results available

Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)

NCT01069523
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Guanfacine Extended Release, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
6 Years to 12 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Jul 24, 2026, 5:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects

NCT00935493
View directory record Official record
Conditions
Cognitive Aging
Interventions
Guanfacine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
75 Years and older
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Jul 24, 2026, 5:03 AM EDT